个人中心 - 老虎社区

Babu95

IP属地：未知

帖子 · 5帖子 · 5
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Babu95Babu95
  ·2021-06-24
  👍🏻
  非常抱歉，此主贴已删除
  298 评论
  点赞
  分享
  举报
- Babu95Babu95
  ·2021-06-20
  Good
  3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%
  Meme stocks have been all the rage so far this year. That's understandable, with several of them del
  3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%
  193 评论
  1
  分享
  举报
- Babu95Babu95
  ·2021-06-16
  Hl💪🏻
  2 Reasons Netflix Will Win Its Merchandising Gambit
  The leading premium streaming video service has an online store. It's bigger than you think.
  2 Reasons Netflix Will Win Its Merchandising Gambit
  139 评论
  点赞
  分享
  举报
- Babu95Babu95
  ·2021-06-15
  Tell me your opinion about this news...
  非常抱歉，此主贴已删除
  180 评论
  点赞
  分享
  举报
- Babu95Babu95
  ·2021-06-12
  Good
  Biotech Finds Market Love at Last as Meme Traders, FDA Converge
  (Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial
  Biotech Finds Market Love at Last as Meme Traders, FDA Converge
  177 评论
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582015879656420","uuid":"3582015879656420","gmtCreate":1618922204199,"gmtModify":1618928125027,"name":"Babu95","pinyin":"babu95","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":128059689,"gmtCreate":1624496034341,"gmtModify":1634005316574,"author":{"id":"3582015879656420","authorId":"3582015879656420","name":"Babu95","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582015879656420","authorIdStr":"3582015879656420"},"themes":[],"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128059689","repostId":"2145016997","repostType":4,"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165221067,"gmtCreate":1624147862659,"gmtModify":1634010362373,"author":{"id":"3582015879656420","authorId":"3582015879656420","name":"Babu95","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582015879656420","authorIdStr":"3582015879656420"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165221067","repostId":"1166679093","repostType":4,"repost":{"id":"1166679093","kind":"news","pubTimestamp":1624065234,"share":"https://ttm.financial/m/news/1166679093?lang=&edition=full","pubTime":"2021-06-19 09:13","market":"us","language":"en","title":"3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166679093","media":"fool","summary":"Meme stocks have been all the rage so far this year. That's understandable, with several of them del","content":"<p>Meme stocks have been all the rage so far this year. That's understandable, with several of them delivering triple-digit and even four-digit percentage gains.</p>\n<p>However, what goes up can come down. Analysts don't expect the online frenzy fueling the ginormous jumps for some of the most popular stocks will be sustainable. Here are three meme stocks that Wall Street thinks will plunge by more than 20% within the next 12 months.</p>\n<p>AMC Entertainment</p>\n<p><b>AMC Entertainment</b>(NYSE:AMC)ranks as the best-performing meme stock of all. Shares of the movie theater operator have skyrocketed close to 2,500% year to date.</p>\n<p>The consensus among analysts, though, is that the stock could lose 90% of its current value. Even the most optimistic analyst surveyed by Refinitiv has a price target for AMC that's more than 70% below the current share price.</p>\n<p>But isn't AMC's business picking up? Yep. The easing of restrictions has enabled the company to reopen 99% of its U.S. theaters. AMC could benefit as seating capacity limitations imposed by state and local governments are raised. Thereleases of multiple movies this summerand later this year that are likely to be hits should also help.</p>\n<p>However, Wall Street clearly believes that AMC's share price has gotten way ahead of its business prospects. The stock is trading at nearly eight times higher than it was before the COVID-19 pandemic.</p>\n<p>Clover Health Investments</p>\n<p>Only a few days ago, it looked like&nbsp;<b>Clover Health Investments</b>(NASDAQ:CLOV)might push AMC to the side as the hottest meme stock. Retail investors viewed Clover as a primeshort squeezecandidate.</p>\n<p>Since the beginning of June, shares of Clover Health have jumped more than 65%. Analysts, however, don't expect those gains to last. The average price target for the stock is 25% below the current share price.</p>\n<p>Clover Health's valuation does seem to have gotten out of hand. The healthcare stock currently trades at more than 170 times trailing-12-month sales. That's a nosebleed level, especially considering that the company is the subject of investigations by the U.S. Department of Justice and the Securities and Exchange Commission.</p>\n<p>Still, Clover Health could deliver improving financial results this year. The company hopes to significantly increase its membership by targeting the original Medicare program. This represents a major new market opportunity in addition to its current Medicare Advantage business.</p>\n<p>Sundial Growers</p>\n<p>At one point earlier this year,&nbsp;<b>Sundial Growers</b>(NASDAQ:SNDL)appeared to be a legitimate contender to become the biggest winner among meme stocks. The Canadian marijuana stock vaulted more than 520% higher year to date before giving up much of its gains. However, Sundial's share price has still more than doubled in 2021.</p>\n<p>Analysts anticipate that the pot stock could fall even further. The consensus price target for Sundial reflects a 23% discount to its current share price. One analyst even thinks the stock could sink 55%.</p>\n<p>There certainly are reasons to be pessimistic about Sundial's core cannabis business. The company's net cannabis revenue fell year over year in the first quarter of 2021. Although Sundial is taking steps that it hopes will turn things around, it remains to be seen if those efforts will succeed.</p>\n<p>Sundial's business deals could give investors reasons for optimism. After all, the company posted positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in Q1 due to its investments.</p>\n<p>However, the cash that Sundial is using to make these investments has come at the cost of increased dilution of its stock. The company can't afford any additional dilution without having to resort to desperate measures to keep its listing on the&nbsp;<b>Nasdaq</b>&nbsp;stock exchange.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Meme Stocks Wall Street Predicts Will Plunge More Than 20%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-19 09:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/18/3-meme-stocks-wall-street-predicts-will-plunge-mor/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meme stocks have been all the rage so far this year. That's understandable, with several of them delivering triple-digit and even four-digit percentage gains.\nHowever, what goes up can come down. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/3-meme-stocks-wall-street-predicts-will-plunge-mor/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/18/3-meme-stocks-wall-street-predicts-will-plunge-mor/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166679093","content_text":"Meme stocks have been all the rage so far this year. That's understandable, with several of them delivering triple-digit and even four-digit percentage gains.\nHowever, what goes up can come down. Analysts don't expect the online frenzy fueling the ginormous jumps for some of the most popular stocks will be sustainable. Here are three meme stocks that Wall Street thinks will plunge by more than 20% within the next 12 months.\nAMC Entertainment\nAMC Entertainment(NYSE:AMC)ranks as the best-performing meme stock of all. Shares of the movie theater operator have skyrocketed close to 2,500% year to date.\nThe consensus among analysts, though, is that the stock could lose 90% of its current value. Even the most optimistic analyst surveyed by Refinitiv has a price target for AMC that's more than 70% below the current share price.\nBut isn't AMC's business picking up? Yep. The easing of restrictions has enabled the company to reopen 99% of its U.S. theaters. AMC could benefit as seating capacity limitations imposed by state and local governments are raised. Thereleases of multiple movies this summerand later this year that are likely to be hits should also help.\nHowever, Wall Street clearly believes that AMC's share price has gotten way ahead of its business prospects. The stock is trading at nearly eight times higher than it was before the COVID-19 pandemic.\nClover Health Investments\nOnly a few days ago, it looked like Clover Health Investments(NASDAQ:CLOV)might push AMC to the side as the hottest meme stock. Retail investors viewed Clover as a primeshort squeezecandidate.\nSince the beginning of June, shares of Clover Health have jumped more than 65%. Analysts, however, don't expect those gains to last. The average price target for the stock is 25% below the current share price.\nClover Health's valuation does seem to have gotten out of hand. The healthcare stock currently trades at more than 170 times trailing-12-month sales. That's a nosebleed level, especially considering that the company is the subject of investigations by the U.S. Department of Justice and the Securities and Exchange Commission.\nStill, Clover Health could deliver improving financial results this year. The company hopes to significantly increase its membership by targeting the original Medicare program. This represents a major new market opportunity in addition to its current Medicare Advantage business.\nSundial Growers\nAt one point earlier this year, Sundial Growers(NASDAQ:SNDL)appeared to be a legitimate contender to become the biggest winner among meme stocks. The Canadian marijuana stock vaulted more than 520% higher year to date before giving up much of its gains. However, Sundial's share price has still more than doubled in 2021.\nAnalysts anticipate that the pot stock could fall even further. The consensus price target for Sundial reflects a 23% discount to its current share price. One analyst even thinks the stock could sink 55%.\nThere certainly are reasons to be pessimistic about Sundial's core cannabis business. The company's net cannabis revenue fell year over year in the first quarter of 2021. Although Sundial is taking steps that it hopes will turn things around, it remains to be seen if those efforts will succeed.\nSundial's business deals could give investors reasons for optimism. After all, the company posted positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in Q1 due to its investments.\nHowever, the cash that Sundial is using to make these investments has come at the cost of increased dilution of its stock. The company can't afford any additional dilution without having to resort to desperate measures to keep its listing on the Nasdaq stock exchange.","news_type":1,"symbols_score_info":{"AMC":0.9,"CLOV":0.9,"SNDL":0.9}},"isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169333780,"gmtCreate":1623816430740,"gmtModify":1634027648250,"author":{"id":"3582015879656420","authorId":"3582015879656420","name":"Babu95","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582015879656420","authorIdStr":"3582015879656420"},"themes":[],"htmlText":"Hl💪🏻","listText":"Hl💪🏻","text":"Hl💪🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169333780","repostId":"1137428482","repostType":4,"repost":{"id":"1137428482","kind":"news","pubTimestamp":1623815725,"share":"https://ttm.financial/m/news/1137428482?lang=&edition=full","pubTime":"2021-06-16 11:55","market":"us","language":"en","title":"2 Reasons Netflix Will Win Its Merchandising Gambit","url":"https://stock-news.laohu8.com/highlight/detail?id=1137428482","media":"Motley Fool","summary":"The leading premium streaming video service has an online store. It's bigger than you think.","content":"<p>It's easy to be skeptical about last week's launch of&nbsp;<b>Netflix</b>'s(NASDAQ:NFLX)&nbsp;online merch store. The new platform -- available via&nbsp;Netflix.shop-- is limited to selling T-shirts and hoodies themed to its<i>Yasuke</i>and<i>Eden</i>anime. It's just designer streetwear right now, and it's not cheap. T-shirts range in price from $30 to $45. Hypland's Yasuke hoodie is going to set you back a beefy $82, or nearly half a year of a Netflix subscription.</p>\n<p>However, you may want to think twice before you dismiss the leading premium video service's chances here. There are some good reasons to bet on Netflix's latest move. Let's check them out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/434a5606f0aa105dc2200617936db7bd\" tg-width=\"2000\" tg-height=\"1333\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Netflix is just getting started</b></p>\n<p>This is obviously just the opening act of Netflix.shop. You can get third-party -- admittedly unlicensed -- shirts for a lot less elsewhere. It will be harder to duplicate the<i>Yasuke</i>and<i>Eden</i>action figures that Netflix is promising will roll out later this month.</p>\n<p>Limited-edition apparel and decor inspired by<i>Lupin</i>-- with the second season just dropping into your Netflix queue -- will hit the digital storefront this month. Last week's launch also teased upcoming exclusive<i>Stranger Things</i>and<i>The Witcher</i>product lines. Reports also have Netflix working on a<i>Bridgerton</i>clothing line alongside live events. And Fans of<i>La Casa de Papel</i>-- aka<i>Money Heist</i>-- should be on the lookout for proprietary merch.</p>\n<p>Don't judge Netflix's new foray into the e-tail of physical merch based on what you see on today's landing page. The store will get bigger, and you'll get there once they roll around to paddling a new revenue stream based on one of your favorite shows.</p>\n<p><b>2. Never underestimate the Netflix audience</b></p>\n<p>It's not smart to bet against Netflix. It doesn't make a move unless it has thoroughly thought things through. How many times were we asking Netflix to rent video games by mail during its red envelope days? How many analysts have wondered about the money that Netflix could rake in it if sold ads on top of its streams in this era of rising connected-TV rates?</p>\n<p>Netflix is way smarter than me. It may also be smarter than you when it comes to how it runs its business. Bloomberg is reporting that Netflix is in the process of hiring heads of consumer products, podcasts, and video game businesses that don't currently exist. If they see the light of day -- as we're seeing with consumer product -- it's because the company knows what it's doing.</p>\n<p>Netflix had&nbsp;207.6 million subscribersat the end of March, and we're talking about entire families here. The reach and breadth is larger than the account base. It's a captive audience spending hours a day getting lost in Netflix's growing digital catalog of content.</p>\n<p>Folks trust Netflix to get it right. They stick around, even if it means prices keep moving higher. Netflix has increased its monthly rates in the U.S.five times over the last seven years, and the sub count is always higher by the time the next hike rolls around.</p>\n<p>Netflix is a&nbsp;media stock. It's not a surprise that traditional media behemoths are generating significant sums of incremental revenue through vibrant consumer product sales. Why wouldn't Netflix -- a company that's been collecting gobs of data on your viewing habits for years -- be as good at nailing what you'll want to buy next as it is at knowing what you want to view next? We may never see a theme park, though I would be the first in line through the turnstiles of Netflixlandia to ride the<i>Ozark</i>roller coaster or experience the<i>Stranger Things</i>dark ride. Selling unique merch to an engaged audience will be a lot easier, and unlike that<i>Ozark</i>coaster there are no height requirements or seat restraints to keep you from making the most of the consumer products ride.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Reasons Netflix Will Win Its Merchandising Gambit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Reasons Netflix Will Win Its Merchandising Gambit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 11:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/15/2-reasons-netflix-will-win-its-merchandising-gambi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's easy to be skeptical about last week's launch of Netflix's(NASDAQ:NFLX) online merch store. The new platform -- available via Netflix.shop-- is limited to selling T-shirts and hoodies themed to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/2-reasons-netflix-will-win-its-merchandising-gambi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/15/2-reasons-netflix-will-win-its-merchandising-gambi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137428482","content_text":"It's easy to be skeptical about last week's launch of Netflix's(NASDAQ:NFLX) online merch store. The new platform -- available via Netflix.shop-- is limited to selling T-shirts and hoodies themed to itsYasukeandEdenanime. It's just designer streetwear right now, and it's not cheap. T-shirts range in price from $30 to $45. Hypland's Yasuke hoodie is going to set you back a beefy $82, or nearly half a year of a Netflix subscription.\nHowever, you may want to think twice before you dismiss the leading premium video service's chances here. There are some good reasons to bet on Netflix's latest move. Let's check them out.\nIMAGE SOURCE: GETTY IMAGES.\n1. Netflix is just getting started\nThis is obviously just the opening act of Netflix.shop. You can get third-party -- admittedly unlicensed -- shirts for a lot less elsewhere. It will be harder to duplicate theYasukeandEdenaction figures that Netflix is promising will roll out later this month.\nLimited-edition apparel and decor inspired byLupin-- with the second season just dropping into your Netflix queue -- will hit the digital storefront this month. Last week's launch also teased upcoming exclusiveStranger ThingsandThe Witcherproduct lines. Reports also have Netflix working on aBridgertonclothing line alongside live events. And Fans ofLa Casa de Papel-- akaMoney Heist-- should be on the lookout for proprietary merch.\nDon't judge Netflix's new foray into the e-tail of physical merch based on what you see on today's landing page. The store will get bigger, and you'll get there once they roll around to paddling a new revenue stream based on one of your favorite shows.\n2. Never underestimate the Netflix audience\nIt's not smart to bet against Netflix. It doesn't make a move unless it has thoroughly thought things through. How many times were we asking Netflix to rent video games by mail during its red envelope days? How many analysts have wondered about the money that Netflix could rake in it if sold ads on top of its streams in this era of rising connected-TV rates?\nNetflix is way smarter than me. It may also be smarter than you when it comes to how it runs its business. Bloomberg is reporting that Netflix is in the process of hiring heads of consumer products, podcasts, and video game businesses that don't currently exist. If they see the light of day -- as we're seeing with consumer product -- it's because the company knows what it's doing.\nNetflix had 207.6 million subscribersat the end of March, and we're talking about entire families here. The reach and breadth is larger than the account base. It's a captive audience spending hours a day getting lost in Netflix's growing digital catalog of content.\nFolks trust Netflix to get it right. They stick around, even if it means prices keep moving higher. Netflix has increased its monthly rates in the U.S.five times over the last seven years, and the sub count is always higher by the time the next hike rolls around.\nNetflix is a media stock. It's not a surprise that traditional media behemoths are generating significant sums of incremental revenue through vibrant consumer product sales. Why wouldn't Netflix -- a company that's been collecting gobs of data on your viewing habits for years -- be as good at nailing what you'll want to buy next as it is at knowing what you want to view next? We may never see a theme park, though I would be the first in line through the turnstiles of Netflixlandia to ride theOzarkroller coaster or experience theStranger Thingsdark ride. Selling unique merch to an engaged audience will be a lot easier, and unlike thatOzarkcoaster there are no height requirements or seat restraints to keep you from making the most of the consumer products ride.","news_type":1,"symbols_score_info":{"NFLX":0.9}},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184644646,"gmtCreate":1623714329285,"gmtModify":1634029812163,"author":{"id":"3582015879656420","authorId":"3582015879656420","name":"Babu95","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582015879656420","authorIdStr":"3582015879656420"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184644646","repostId":"1197453683","repostType":4,"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":186973216,"gmtCreate":1623471233435,"gmtModify":1634032688419,"author":{"id":"3582015879656420","authorId":"3582015879656420","name":"Babu95","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582015879656420","authorIdStr":"3582015879656420"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/186973216","repostId":"2142025622","repostType":4,"repost":{"id":"2142025622","kind":"news","pubTimestamp":1623442528,"share":"https://ttm.financial/m/news/2142025622?lang=&edition=full","pubTime":"2021-06-12 04:15","market":"us","language":"en","title":"Biotech Finds Market Love at Last as Meme Traders, FDA Converge","url":"https://stock-news.laohu8.com/highlight/detail?id=2142025622","media":"Bloomberg","summary":"(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial","content":"<p><img src=\"https://static.tigerbbs.com/8cda5e1416d8765a6009019a2442b35a\" tg-width=\"1200\" tg-height=\"675\"></p>\n<p>(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. Now investors are taking a second look at the sector.</p>\n<p>With biotech having trailed the broader market for the past three months and chock full of companies that have been the focus of short sellers, it was catnip for the Reddit crowd. Indeed, the price action wrought havoc across the health-care sector after shorts lost over $465 million on Clover Health Investments Corp. in a single day as the stock nearly doubled.</p>\n<p>The moves weren’t just about amateur traders or punishing the shorts. Specialists who live and breathe biotech received two of three critical updates that have been hailed as the impetus for a broad return of investor interest. That includes approval from the Food and Drug Administration of an Alzheimer’s disease drug from Biogen Inc.</p>\n<p>“One of the clouds overhanging the sector went away this week, it’s a very good sign,” Brad Loncar, chief executive officer of Loncar Investments, said of the FDA decision.</p>\n<p>Monday’s decision by the FDA to approve Aduhelm, the first new medicine for the disease in decades, came despite mixed clinical trials, stunning analysts and buoying the sector. More than 15 million shares in the $11 billion <a href=\"https://laohu8.com/S/EEME\">iShares</a> Nasdaq Biotechnology ETF (IBB) changed hands, the highest daily level since June 2017. The index ended the week up 6%.</p>\n<p>It wasn’t all good news for these drugmakers. Aduhelm’s $56,000 a year price tag and a setback for Vertex Pharmaceuticals Inc. tempered the rally. The cost of the Biogen drug renewed concern about a regulatory clampdown on pricing, while Vertex announced that it had halted development of a liver disease treatment that the company said was unlikely to have a clinical benefit for patients. Shares of the drug developer plunged 11% on Friday and it’s the worst performer among large-cap biotechs, falling 18% so far this year.</p>\n<p>There’s <a href=\"https://laohu8.com/S/AONE\">one</a> more key readout biotech investors are waiting on: results from a trial in major depression from Biogen and its partner <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> Inc. With a win for Biogen and a loss for Vertex, the Biogen-Sage results could very well determine which direction biotech goes next, according to RBC analyst Brian Abrahams. The data are expected by the end of June.</p>\n<p>A recent Goldman Sachs survey of 75 investors at the bank’s health-care conference highlights the ongoing uncertainty, with 47% saying the sector would outperform over the second half of the year while the rest were evenly split between expecting health stocks to underperform or move in-line with the broader market.</p>\n<p><b>M&amp;A Hopes</b></p>\n<p>Vertex’s recent failure also came with a silver lining: the potential for a deal to bolster its pipeline. “Management has signaled a new openness to later-stage deals, and the shelving of VX-864 may now force its hand,” Bloomberg Intelligence analyst Marc Engelsgjerd wrote in a note.</p>\n<p>The pace of deals in the first half can determine the direction of biotechs for the rest of 2021, with years that start off with five or more deals over $500 million usually driving the outperformance of nearly 4% for the Nasdaq Biotech index, according to JPMorgan’s analysis.</p>\n<p>As biotech specialists weighed the catalysts for further gains, an 86% jump for Chamath Palihapitiya-backed health insurer Clover drove interest toward once high-flying biotechs with highly shorted floats and mediocre analyst ratings. <a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals Inc</a>., which recently lost U.S. government funding for its Covid shot, and <a href=\"https://laohu8.com/S/CLVS\">Clovis Oncology</a> Inc., a fallen former M&amp;A target with a disappointing cancer drug, popped this week as day traders targeted short-squeeze candidates.</p>\n<p>Retail traders have also been driving triple-digit and even quadruple-digit gains in obscure biotech names like Ocugen Inc., a drug developer with plans to bring a Covid-19 vaccine to the U.S., and <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>., a 20-year old biotech whose main product isn’t yet in the final stages of testing.</p>\n<p>Loncar at least is unfazed by biotechs joining the meme parade. “Professionals understand what the true intrinsic value of a biotech is,” he said in an interview. “Unlike GameStop or AMC, a biotech either has good science or it doesn’t.”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Finds Market Love at Last as Meme Traders, FDA Converge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Finds Market Love at Last as Meme Traders, FDA Converge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-12 04:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/biotech-finds-market-love-last-201528495.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2142025622","content_text":"(Bloomberg) -- Unloved biotech stocks posted the best week since November, fueled by a controversial regulatory decision and a legion of Reddit fans, burning a bunch of short sellers along the way. Now investors are taking a second look at the sector.\nWith biotech having trailed the broader market for the past three months and chock full of companies that have been the focus of short sellers, it was catnip for the Reddit crowd. Indeed, the price action wrought havoc across the health-care sector after shorts lost over $465 million on Clover Health Investments Corp. in a single day as the stock nearly doubled.\nThe moves weren’t just about amateur traders or punishing the shorts. Specialists who live and breathe biotech received two of three critical updates that have been hailed as the impetus for a broad return of investor interest. That includes approval from the Food and Drug Administration of an Alzheimer’s disease drug from Biogen Inc.\n“One of the clouds overhanging the sector went away this week, it’s a very good sign,” Brad Loncar, chief executive officer of Loncar Investments, said of the FDA decision.\nMonday’s decision by the FDA to approve Aduhelm, the first new medicine for the disease in decades, came despite mixed clinical trials, stunning analysts and buoying the sector. More than 15 million shares in the $11 billion iShares Nasdaq Biotechnology ETF (IBB) changed hands, the highest daily level since June 2017. The index ended the week up 6%.\nIt wasn’t all good news for these drugmakers. Aduhelm’s $56,000 a year price tag and a setback for Vertex Pharmaceuticals Inc. tempered the rally. The cost of the Biogen drug renewed concern about a regulatory clampdown on pricing, while Vertex announced that it had halted development of a liver disease treatment that the company said was unlikely to have a clinical benefit for patients. Shares of the drug developer plunged 11% on Friday and it’s the worst performer among large-cap biotechs, falling 18% so far this year.\nThere’s one more key readout biotech investors are waiting on: results from a trial in major depression from Biogen and its partner Sage Therapeutics Inc. With a win for Biogen and a loss for Vertex, the Biogen-Sage results could very well determine which direction biotech goes next, according to RBC analyst Brian Abrahams. The data are expected by the end of June.\nA recent Goldman Sachs survey of 75 investors at the bank’s health-care conference highlights the ongoing uncertainty, with 47% saying the sector would outperform over the second half of the year while the rest were evenly split between expecting health stocks to underperform or move in-line with the broader market.\nM&A Hopes\nVertex’s recent failure also came with a silver lining: the potential for a deal to bolster its pipeline. “Management has signaled a new openness to later-stage deals, and the shelving of VX-864 may now force its hand,” Bloomberg Intelligence analyst Marc Engelsgjerd wrote in a note.\nThe pace of deals in the first half can determine the direction of biotechs for the rest of 2021, with years that start off with five or more deals over $500 million usually driving the outperformance of nearly 4% for the Nasdaq Biotech index, according to JPMorgan’s analysis.\nAs biotech specialists weighed the catalysts for further gains, an 86% jump for Chamath Palihapitiya-backed health insurer Clover drove interest toward once high-flying biotechs with highly shorted floats and mediocre analyst ratings. Inovio Pharmaceuticals Inc., which recently lost U.S. government funding for its Covid shot, and Clovis Oncology Inc., a fallen former M&A target with a disappointing cancer drug, popped this week as day traders targeted short-squeeze candidates.\nRetail traders have also been driving triple-digit and even quadruple-digit gains in obscure biotech names like Ocugen Inc., a drug developer with plans to bring a Covid-19 vaccine to the U.S., and Cassava Sciences Inc., a 20-year old biotech whose main product isn’t yet in the final stages of testing.\nLoncar at least is unfazed by biotechs joining the meme parade. “Professionals understand what the true intrinsic value of a biotech is,” he said in an interview. “Unlike GameStop or AMC, a biotech either has good science or it doesn’t.”","news_type":1,"symbols_score_info":{"BIIB":0.9,"VRTX":0.9}},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}